ES2525952A1 - Combinación farmacéutica antineurítica y composiciones - Google Patents

Combinación farmacéutica antineurítica y composiciones Download PDF

Info

Publication number
ES2525952A1
ES2525952A1 ES201490063A ES201490063A ES2525952A1 ES 2525952 A1 ES2525952 A1 ES 2525952A1 ES 201490063 A ES201490063 A ES 201490063A ES 201490063 A ES201490063 A ES 201490063A ES 2525952 A1 ES2525952 A1 ES 2525952A1
Authority
ES
Spain
Prior art keywords
compositions
antineuritic
pharmaceutical combination
combinations
antiepileptic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201490063A
Other languages
English (en)
Other versions
ES2525952B1 (es
Inventor
Héctor SENOSIAIN ARROYO
Maria Angélica ARZOLA PANIAGUA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Senosiain SA de CV
Original Assignee
Laboratorios Senosiain SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48611941&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525952(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Senosiain SA de CV filed Critical Laboratorios Senosiain SA de CV
Publication of ES2525952A1 publication Critical patent/ES2525952A1/es
Application granted granted Critical
Publication of ES2525952B1 publication Critical patent/ES2525952B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Combinación farmacéutica antineurítica y composiciones. La presente invención se refiere a combinaciones farmacéuticas de dos antiepilépticos, así como combinaciones de un antiepiléptico, y vitaminas del complejo B, en donde los antiepilépticos se seleccionan de pregabalina y oxcarbazepina, y las vitaminas se seleccionan de vitamina B1 y vitamina B12. También se refiere a composiciones farmacéuticas que contienen dichas combinaciones y al uso de dichas composiciones para el tratamiento del dolor neuropático (DN).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
    imagen2
ES201490063A 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones Expired - Fee Related ES2525952B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.
MX/A/2011/014042 2011-12-16
PCT/IB2012/057345 WO2013088410A1 (es) 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones

Publications (2)

Publication Number Publication Date
ES2525952A1 true ES2525952A1 (es) 2015-01-02
ES2525952B1 ES2525952B1 (es) 2015-10-05

Family

ID=48611941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201490063A Expired - Fee Related ES2525952B1 (es) 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones

Country Status (14)

Country Link
US (1) US20140323428A1 (es)
BR (1) BR112014014774A2 (es)
CA (1) CA2859487C (es)
CL (1) CL2014001581A1 (es)
CO (1) CO6990712A2 (es)
CR (1) CR20140283A (es)
DO (1) DOP2014000134A (es)
ES (1) ES2525952B1 (es)
GT (1) GT201400115A (es)
MX (1) MX336979B (es)
NI (1) NI201400058A (es)
PE (1) PE20141688A1 (es)
PL (1) PL231163B1 (es)
WO (1) WO2013088410A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826470B1 (en) * 2013-07-19 2017-09-06 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of pregabalin
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006127475A (ru) * 2003-12-29 2008-02-10 Джейсон МАКДЭВИТТ (US) Композиции и способы лечения рецидивирующих медицинских состояний
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
US8394759B2 (en) * 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes

Also Published As

Publication number Publication date
GT201400115A (es) 2017-07-27
US20140323428A1 (en) 2014-10-30
MX336979B (es) 2016-02-09
BR112014014774A2 (pt) 2017-06-13
DOP2014000134A (es) 2014-07-31
CL2014001581A1 (es) 2014-09-26
WO2013088410A1 (es) 2013-06-20
PL231163B1 (pl) 2019-01-31
NI201400058A (es) 2014-12-22
CO6990712A2 (es) 2014-07-10
ES2525952B1 (es) 2015-10-05
CR20140283A (es) 2015-03-11
CA2859487C (en) 2016-11-15
CA2859487A1 (en) 2013-06-20
PE20141688A1 (es) 2014-12-03
PL409542A1 (pl) 2015-07-20
MX2011014042A (es) 2013-06-17

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
EA201890754A1 (ru) Соединения и способы их применения
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
EA201490688A1 (ru) 2-тиопиримидиноны
CL2013002394A1 (es) Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
CO2017011295A2 (es) Piroglutamato de vortioxetina
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
HK1255345A1 (zh) 含有高濃度紫杉烷的用於口服給藥的藥物組合物
ECSP13012679A (es) Composiciones farmacéuticas que comprenden alisporivir
BR112017023539A2 (pt) composições para limpeza de cólon e tratamento de distúrbios gastrointestinais
ES2525952A1 (es) Combinación farmacéutica antineurítica y composiciones
EA201591480A1 (ru) Способы лечения дискинезии и сопутствующих расстройств
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
MX356102B (es) Compuestos y métodos para tratar leucemia.
EP3270883C0 (en) SCALABLE UNIT DOSAGE FORM OF A VITAMIN COMPOSITION FOR THE TREATMENT OF A DEFICIENCY IN LIPOSOLUBLE VITAMINS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2525952

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151005

FD2A Announcement of lapse in spain

Effective date: 20220426